Metformin Stada

Metformin, the active ingredient in Metformin Stada, is a biguanide presented as a tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes and to address metabolic disturbances in polycystic ovary syndrome. GNH USA supplies Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Stada belongs to the biguanide class and is indicated for conditions that involve impaired glucose regulation. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Polycystic ovary syndrome: improves insulin resistance and may help restore ovulatory cycles.

Metformin Stada may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia. - Diarrhoea: often mild to moderate in intensity. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: long‑term use may lower serum levels.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe hypoglycaemia: typically when combined with other glucose‑lowering agents. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Allergic skin reactions: rash, urticaria, or Stevens‑Johnson syndrome. - Pancreatitis: inflammation of the pancreas. - Anemia: unexplained reduction in red blood cell count.

Metformin Stada requires careful patient assessment and monitoring to minimise risks. - Renal function assessment: evaluate kidney function before initiating and periodically monitor. - Lactic acidosis risk: avoid in patients with significant renal or hepatic impairment. - Cardiovascular status: use cautiously in patients with heart failure. - Pregnancy and lactation: safety not established; discuss risks with a healthcare provider. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Metformin Stada can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction; discontinue before imaging. - Cimetidine: can increase metformin plasma levels, raising risk of lactic acidosis. - Alcohol excess: potentiates risk of lactic acidosis. - Renal toxic drugs (e.g., NSAIDs, aminoglycosides): may impair renal clearance. - SGLT2 inhibitors: combined use requires close monitoring for metabolic disturbances.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal function and electrolyte balance. - Thyroid hormones: may alter glucose metabolism. - Corticosteroids: may increase blood glucose, requiring dose adjustment. - ACE inhibitors: monitor renal function when used together.